Quarterly ResultMay 13, 2026, 04:14 PM
Aquestive Therapeutics Q1 Revenue +65.7%; Net Loss Cut to $8.06M
AI Summary
Aquestive Therapeutics reported a significant improvement in its first quarter 2026 financial results, with total revenues increasing by 65.7% to $14.45 million compared to the prior year. The company substantially reduced its net loss to $8.06 million from $22.93 million in Q1 2025, driven by higher license and royalty revenue, including a $4.5 million royalty from Zevra, and lower operating expenses. Aquestive ended the quarter with $110.73 million in cash and cash equivalents, indicating sufficient liquidity for the next twelve months.
Key Highlights
- Total revenues increased 65.7% to $14.45 million in Q1 2026 from $8.72 million in Q1 2025.
- Net loss significantly reduced to $8.06 million in Q1 2026 from $22.93 million in Q1 2025.
- Basic and diluted loss per share improved to $(0.07) in Q1 2026 from $(0.24) in Q1 2025.
- License and royalty revenue surged to $5.40 million in Q1 2026, including $4.50 million from Zevra.
- Research and development expenses decreased to $4.20 million in Q1 2026 from $5.36 million in Q1 2025.
- Selling, general and administrative expenses fell to $10.98 million in Q1 2026 from $19.07 million in Q1 2025.
- Cash and cash equivalents stood at $110.73 million as of March 31, 2026.
- Net cash used for operating activities decreased to $14.81 million from $23.40 million year-over-year.
Price Impact
More from AQST